Navigation Links
YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain

an, Chairman and CEO of YM BioSciences. "We look forward to completing a detailed analysis of the numerous secondary endpoints and safety data from this study to extend the information we will make available. These results will also be used to enhance the design of the additional Phase II trial that we are planning for the U.S. as well as the eventual Phase III trial."

Clinical Trial Design

The Phase IIb clinical study (DLXLEF-AP4) was a 2-part, multi-center study to evaluate the efficacy, safety and tolerability of repeated, self-titrated inhalation of AeroLEF(TM) for the treatment of acute post-operative pain following orthopedic surgery. Part 1 of the study was a 21 patient open-label, lead-in study to ensure consistency of AeroLEF(TM) administration across study sites. Results of Part I of the Phase IIb study were presented at the 2006 American Society of Anesthesiologists (ASA) Annual Meeting in Chicago, IL.

Part 2 was a 99 patient randomized, placebo-controlled study. The treatment phase of the study began in the post-anesthetic care unit (PACU) after completion of surgery when the patient reported a pain intensity score (PI) of at least 2 (moderate pain) on a 4-point verbal rating scale (0 (none) to 3 (severe pain)). The clinical trial study period was up to 12 hours and patients were allowed to self-administer AeroLEF(TM) to treat up to two additional pain episodes during the study period.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to seve
'"/>




Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:7/23/2014)... 2014 The Board of Directors of VirtualScopics, ... of clinical trial imaging solutions, announced today that ... and chief executive officer, effective immediately.  Mr. Converse joined ... has held the positions of interim president and chief ... Charles E. Phelps , Ph.D., chairman of the ...
(Date:7/23/2014)... , July 23, 2014 ... PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION ... RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. AbbVie ... financial results on Friday, July 25, 2014, before the market ... the earnings conference call at 8 a.m. Central time (9 ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Use of ... access programs to delay generic market entry results in ... a new survey and analysis by economic consulting ... Logo - http://photos.prnewswire.com/prnh/20140723/129680 Required by ... drugs and biologics, REMS programs are intended to improve ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
... Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... against cancers and infectious diseases, has expanded its scientific ... in the fields of vaccines and cancer immunotherapeutics. Joining ... Professor of the Scripps Research Institute and founder of ...
... The Board of Directors of MSA (NYSE: MSA ... President of the company, responsible for Global Product Leadership.  Dr. ... 1, will assume the role of President of MSA International, ... his new role, Dr. Muschter will become a member of ...
Cached Medicine Technology:Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 2Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 3Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 4Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 5MSA Elects Dr. Thomas Muschter to Vice President 2
(Date:7/23/2014)... 2014 A new study has uncovered ... ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive hysterectomies can ... woman’s body, Bernstein Liebhard LLP reports. The research, which ... the American Medical Association, looked at 36,000 women who ... U.S. hospitals from 2006 to 2012. Ninety-nine of the ...
(Date:7/23/2014)... suspicious skin lesion is painful or itchy may help ... cancerous, according to a new study headed by Gil ... Temple University School of Medicine. , The study, published ... 2014, found that nearly 36. 9 percent of skin ... involve pain. Non-melanoma skin cancers specifically, basal cell ...
(Date:7/23/2014)... WEDNESDAY, July 23, 2014 (HealthDay News) -- Painful or ... skin cancer, researchers report. "Patients sometimes have multiple ... itchy or painful should raise high concerns for non-melanoma ... dermatology at Temple University School of Medicine, said in ... looked at the medical records of 268 patients who ...
(Date:7/23/2014)... Coral, FL (PRWEB) July 23, 2014 Rich ... announce the success of their charity yard sale to support ... was raised and 100% of the proceeds will be donated ... at the event are being donated to the Habitat for ... Fort Myers, Florida 33903. , One of the highlights ...
(Date:7/23/2014)... Fragile X syndrome ( FXS ) is a genetic ... behaviors on the autistic spectrum, as well as cognitive ... mental impairment and the most common cause of autism. ... Riverside have published a study that sheds ... Appearing online today (July 23) in the Journal ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
... it was found that triple drug therapy helped people suffer ... a clot-preventing drug such as aspirin, an ACE inhibitor for ... that these drugs work synergistically to reduce the amount of ... a neurologist at Harvard Medical School and co-director of the ...
... that women who drink insufficient milk during pregnancy probably to ... inhibit// their babies’ growth in the womb. ,The ... Association Journal. 300 women took part in the study. All ... babies of mothers who drank at least a cup of ...
... to lead can induce hypertension in lab animals and more ... adults too. But till now nothing concrete was known about ... to expose to lead for five years researchers have found ... ,Lead's most widely documented effects are neurological. Exposure ...
... will become the benchmark against which the growth of babies ... from the practice of almost 4 decades, //where babies have ... growth pattern portrayed by formula- fed babies. ,It ... rate as compared to breast fed infants and this makes ...
... the American Civil Liberties Union are questioning the policy ... and customs agents to detain travelers //who look like ... is reportedly available with Reuters, also allows Customs and ... ,Health and Human Services Secretary ...
... the advertisement on junk foods shown on television poses ... by tempting them to go for it thereby leading ... foodconsumer.org, previous studies have already associated childhood overweight with ... link between childhood overweight and TV viewing is due ...
Cached Medicine News:Health News:Limiting milk can hamper Babies’ Growt 2Health News:Exposure To Lead Doesn’t Cause Hypertension In Childre 2Health News:Junk Food Ads: The Culprit Behind Childhood Obesity 2
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
Medicine Products: